Rigel Pharmaceuticals Inc
RIGL· Nasdaq
RIGLRigel Pharmaceuticals Inc
Released May 5, 2026, after the close
10-Q filed May 5, 2026, 35 days after period end · 0001034842-26-000032
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | $58.82M | $53.33M | $29.53M | $26.07M |
| Net Income | $8.65M | $11.45M | -$8.25M | -$13.54M |
| EPS Diluted |
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR
| $0.44 |
| $0.63 |
| -$0.47 |
| -$0.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
